| EYEPOINT INC. DL-,01 |
| USA |
| Gesundheit |
| US30233G2093 / A2QJRU |
| PV3B (Frankfurt) / EYPT (NASDAQ) |
| FRA:PV3B, ETR:PV3B, PV3B:GR, NASDAQ:EYPT |
| - |
| https://eyepointpharma.co.. |
|
EyePoint Pharmaceuticals Inc. is a specialty biopharmaceutical company focused on developing and commercializing innovative ophthalmic products. Its primary purpose is to treat serious eye disorders, particularly targeting diseases like wet age-relat..
>Volltext.. |
| 1099.13 Mio. EUR |
| 962.47 Mio. EUR |
| 2.41 Mio. EUR |
| -271.73 Mio. EUR |
| -265.05 Mio. EUR |
| -3.24 EUR |
| 19.33 Mio. EUR |
| 95.47 Mio. EUR |
| -231.04 Mio. EUR |
| 4.3 |
| -94.63% |
| -74.84% |
| - |
| - |
| - |
| - |
| EYEPOINT |
| 17.08.26 |